Table 1.
Patient and tumor characteristics
| Characteristics | No. of patients (%) | |
|---|---|---|
| Age (years) |
Median (Range) |
60 (39–79) |
| ≤ 60 |
43 (52) |
|
| > 60 |
39 (48) |
|
| Gender |
Male |
60 (73) |
| Female |
22 (27) |
|
| Etiology |
Hepatitis B virus |
55 (67) |
| Hepatitis C virus |
7 ( 9) |
|
| Others |
20 (24) |
|
| Diagnosis history at SBRT |
Initially diagnosed |
28 (34) |
| Diagnose as recurrence |
54 (66) |
|
| No. of previous TACE sessions |
≤ 2 |
44 (54) |
| > 2 |
38 (46) |
|
| Alpha-fetoprotein (IU/ml) |
Median (Range) |
14.0 (1.3–6055) |
| ≤ 200 |
60 (73) |
|
| > 200 |
22 (27) |
|
| Child-Turcotte-Pugh score |
A5 |
61 (74) |
| A6 |
13 (16) |
|
| B7 |
8 (10) |
|
| Portal vein tumor thrombosis |
Yes |
8 (10) |
| No |
74 (90) |
|
| No. of tumor |
1 |
71 (87) |
| 2* |
9 (11) |
|
| 3* |
2 (2) |
|
| AJCC stage |
T1 |
44 (54) |
| T2 |
16 (19) |
|
| T3 |
22 (27) |
|
| BCLC stage |
A |
43 (53) |
| B |
24 (29) |
|
| C |
15 (18) |
|
| Okuda stage |
I |
64 (78) |
| II |
18 (22) |
|
| CLIP score |
0 |
39 (48) |
| 1 |
32 (39) |
|
| 2 |
11 (13) |
|
| Longest diameter (cm) |
Median (Range) |
3.0 (1.0–7.0) |
| 1.0-2.0 |
10 (12) |
|
| 2.1-3.0 |
23 (28) |
|
| 3.1-4.0 |
22 (27) |
|
| 4.1-5.0 |
13 (16) |
|
| 5.1-6.0 |
4 (5) |
|
| 6.1-7.0 |
10 (12) |
|
| SBRT dose (Gy) |
Median (Range) |
51 (33–60) |
| < 45 |
32 (39) |
|
| 45–54 |
40 (49) |
|
| > 54 | 10 (12) | |
Abbreviations: SBRT stereotactic body radiotherapy, TACE transarterial chemoembolization, AJCC American Joint Committee on Cancer, BCLC Barcelona Clinic Liver Cancer, CLIP Cancer of the Liver Italian Program.
*All multiple lesions were treated with SBRT in one session.